Medexus Pharmaceuticals Inc (MDP)

Toronto
2.97
-0.04(-1.33%)
  • Volume:
    2,773
  • Bid/Ask:
    2.95/2.99
  • Day's Range:
    2.95 - 3.01
  • Type:Equity
  • Market:Canada
  • ISIN:CA58410Q2036
  • CUSIP:58410Q203

MDP Overview

Prev. Close
3.01
Day's Range
2.95-3.01
Revenue
176.7M
Open
3
52 wk Range
2.6-9.75
EPS
-2.49
Volume
2,773
Market Cap
57.73M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
62,902
P/E Ratio
-
Beta
1.07
1-Year Change
-26.05%
Shares Outstanding
19,178,979
Next Earnings Date
Nov. 29, 2021
What is your sentiment on Medexus Pharmaceuticals Inc?
or
Vote to see community's results!

Medexus Pharmaceuticals Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellStrong SellStrong SellStrong Sell
Technical IndicatorsBuyBuyStrong SellStrong SellStrong Sell
SummaryBuyNeutralStrong SellStrong SellStrong Sell

Medexus Pharmaceuticals Inc Company Profile

Medexus Pharmaceuticals Inc Company Profile

Employees
87
Market
Canada

Medexus Pharmaceuticals Inc. is a Canada-based rare disease pharmaceutical company. The Company is a North American focused, specialty pharmaceutical business that operates through two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada, a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. Medexus Pharma USA, a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States (U.S). The Company is focused on the therapeutic areas of auto-immune disease, hematology, pediatrics, dermatology and allergy. The Company's products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases. It also offers IXINITY, a medicine for use in patients 12 years of age or older with Hemophilia B and Rupall, an allergy medication.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.